DiaVacs Announces Licensing Agreement with University of Pittsburgh for Novel Dendritic Cell and Microsphere Delivery Technologies for Treatment of Type 1 Diabetes

April 29, 2014 DiaVacs today announces that it has entered into a licensing agreement with the¬†University of Pittsburgh¬†for intellectual property pertaining to novel dendritic cell and antisense oligonucleotide microsphere delivery technologies for the treatment of type 1 diabetes. DiaVacs plans to apply this innovative technology to the development of a microsphere formulation of an antisense-nucleotide vaccine. According to initial studies …

Personalized ovarian cancer vaccine trial results look promising

A new ovarian cancer vaccine has shown promise in clinical trials. The cancer vaccine relies on an innovative two-step immunotherapy approach, the first step of which is to manufacture a personalized dendritic cell vaccine by exposing the patient's dendritic cells to tumour tissue collected during surgery. The primed dendritic cells are then sent back into the body to raise the …